The effect of chronic fluxoxamine treatment on overnight melatonin secretion in medicated chronic schizophrenic patients

Human Psychopharmacology

Volumn 12, Issue 1, 1997, Pages 21-25

  Silver, Henry ^a   Barash, Igor ^a   Shmugliakov, Natalie ^a   Odnopozov, Natan ^b  

^a Flugelman Psychiatric Hospital   (Israel)

^b Rivka Zeiff Hospital   (Israel)

Author keywords

fluvoxamine; melatonin; schizophrenia; tolerance

Indexed keywords

FLUVOXAMINE; MELATONIN;

ADULT; ARTICLE; CLINICAL ARTICLE; HORMONE RELEASE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0031038608     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199701/02)12:1<21::AID-HUP821>3.0.CO;2-X     Document Type: Article

References (29)

1. Andreasen, N. C. (1983). Scale for the Assessment of Negative symptoms (SANS). The University of Iowa, Iowa city.
2. Arendt, J. (1989). Melatonin a new probe in psychiatric investigation? British Journal of Psychiatry, 155, 585-590.
3. Beck-Friis, J., Kjellman, B. F., Aperia, B., et al. (1985). Serum melatonin in relation to clinical variables in patients with major depressive disorder and hypothesis of a low melatonin syndrome. Acta Psychiatrica Scandinavica, 71, 319-330.
4. Beck-Friis, J., Von Rosen, D., Kjellman, B. F., Ljunggren, J. and Wetterberg, L. (1984). Serum melatonin in relations to body measures, sex, age, season and the use of drugs in patients with major affective disorder and healthy subjects. Psychoendocrinology, 9, 261-277.
5. Claustrat, B., Chazot, L., Brun, J., Jordan, D. and Sassolas, G. (1984). A chronobiological study of melatonin and cortisol secretion in depressed subjects; plasma melatonin a biological marker in major depression. Biological Psychiatry, 19, 1215-1218.
6. Childs, P. A., Rodin, I., Martin, N. J., Allen, N. H. P., Plaskett, L., Smythe, P. J. and Thompson, C. (1995). Effect of fluoxetine in patients with seasonal affective disorder and matched controls. British Journal of Psychiatry, 166, 196-198.
7. Cowen, P., Green, A. R. and Grahame-Smith, D. G. (1985). Plasma melatonin during desmethylmipramine treatment: evidence for changes in noradrenergic transmission. British Journal of Clinical Pharmacology, 19, 799-805.
8. Daniel, D. G., Randolph, C., Jaskiw, G., Handel, S., Williams, T., Abi-Dargham, A., Shoaf, S., Egan, M., Elkashef, A., Liboff, S., et al., (1994). Co-administration of fluvoxamine increases serum concentrations of haloperidol. Journal of Clinical Psychopharmacology, 14(5), 340-343.
9. Demisch, K., Demisch, L., and Bodinik, H. J. (1986). Melatonin and cortisol increase after fluvoxamine. British Journal of Clinical Pharmacology, 22, 620-622.
10. Demisch, K., Demisch, L, Nickelsen, T. and Reith, R. (1987). The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects increases following fluvoxamine. Journal of Neural Transmission, 68, 257-270.
11. deMontigny C., Chaput, Y. and Blier, P. (1990). Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. Journal of Clinical Psychiatry, 51 (Suppl. B), 4-8.
12. Fanjet, F., Clausrat, B., Dalery, J., et al. (1989). Nocturnal plasma melatonin levels in schizophrenic patients. Biological Psychiatry, 25, 499-501.
13. Ferner, I. N., Arendt, J., Johnstone, E. C. and Crow, T. J. (1982). Reduced nocturnal melatonin secretion in chronic schizophrenia: relationship to body weight. Clinical Endocrinology, 17, 181-187.
14. Franey, C., Aldous, M., Burton, S., et al. (1986) Acute treatment with desipramine stimulates melatonin and 6-sulphatoxymelatonin in man. British Journal of Clinical Pharmacology, 22, 73-79.
15. Hiemke, C., Weigmann, H., Hartter, S., Dahmen, N., Wetzel, H. and Mutler, H. (1994). Elevated levels of clozapine in serum after addition of fluvoxamine (Letter). Journal of Clinical Psychopharmacology, 14(4), 279-281.
16. Jerling, M., Lindstrom, L., Bondesson, U. and Bertilsson, L. (1994). Fluvoxamine inhibition and carbamezapine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Therapeutic Drug Monitoring, 16(4), 368-374.
17. Li, Q., Levy, A. D., Cabrera, T. M., Brownfield, M. S., Battaglia, G. and Van de Kar, L. D. (1993). Long-term fluoxetine, but not desipramine, inhibits the ACTH and oxytocin responses to the 5-HT1A agonist, 8-OH-DPAT, in male rats. Brain Research, 630 (1-2), 148-156.
18. Mendelewicz, J., Linkowski, P., Branchey, L., Weinberg, U. and Weinberg, U. and Weitzman, E. D. (1979). Abnormal 24 hr pattern of melatonin secretion in depression. Lancet, ii, 1362.
19. Ozaki, Y., Lynch, H. J. and Wurtman, R. J. (1976). Melatonin in rat pineal, plasma and urine: 24 hour rhythmicity and effect of chlorpromazine, Endocrinology, 98 (6), 1418-1424.
20. Robinson, S., Rosca, P., Durst, R., Shai, U., Ghinea, G., Schmidt, U. and Nir, I. (1991). Serum melatonin levels in schizophrenic and schizo affective hospitalized patients. Acta Psychiatrica Scandinavica, 84, 221-224.
21. Sack, R. and Lewy, A. J. (1986). Desmethylimipramine treatment increases melatonin production in humans. Biological Psychiatry, 31, 246-248.
22. Silver, H. and Nassar, A. (1992). Fluvoxamine improves negative symptoms in treated chronic schizophrenia. An add-on double-blind placebo-controlled study. Biological Psychiatry 31, 698-704.
23. Silver, H., Kaplan, A. and Kushnir, M. (1995a). Fluvoxamine augmentation in chronic schizophrenia. An open exploratory study. Human Psychopharmacology, 10, 59-63.
24. Silver, H., Barash, I., Odnopozov, N., Jahjah, N. and Mizruhin, A. (1995b). Melatonin response to fluvoxamine in medicated schizophrenic patients. Evidence for the development of tolerance to SSRI. Biological Psychiatry, in press.
25. Silver, H., Odnopozov, N., Jahjah, N. and Barash, I. (1995c). Chronic fluvoxamine treatment reduces platelet MAO activity in medicatec chronic schizophrenics. Human Psychopharmacology, 10, 321-326.
26. Skene, D. J., Bojkowski, C. J. and Arendt, J. (1994). Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. Bristish Journal of Clinical Pharmacology, 37 (2), 181-186.
27. Smith, J.A., Barnes, J. L. and Mee, T. J. (1979). The effect of neuroleptic drugs on serum and cerebrospinal fluid melatonin concentrations in psychiatric patients. Journal of Pharmaceuticals and Pharmacology, 31 (4), 246-248.
28. Thomson, C., Mezey, G., Corn, T., et al. (1985). The effect of desipramine upon melatonin and cortisol secretion in depressed and normal subjects British Journal of Psychiatry, 147, 389-393.
29. Wetterberg, L., Aperia, B., Bech-Friis, J. et al., (1982) Melatonin and cortisol level in psychiatric illness. Lancet, ii, 100.